Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA 90509, USA.
Rev Endocr Metab Disord. 2011 Jun;12(2):107-17. doi: 10.1007/s11154-011-9183-3.
An effective, safe, reversible, and acceptable method of contraception is an important component of reproductive health and provides the opportunity of shared responsibility for family planning for both partners. Female hormonal contraceptives have been proven to be safe, reversible, available and widely acceptable by different populations. In contrast, male hormonal contraception, despite significant progress showing contraceptive efficacy comparable to female hormonal methods during last three decades, has not yet led to an approved product. Safety of a pharmaceutical product is an appropriate concern but the majority of male hormonal contraceptive clinical trials have not reported significant short term safety concerns. While the absence of serious adverse effects is encouraging, the studies have been designed for efficacy endpoints not long term safety. In this review we summarize potential risks and benefits of putative male hormonal contraceptives on reproductive and non-reproductive organs. While the review covers what we believe will be the likely class of drugs used for male hormonal contraception a true assessment of long term risks and benefits cannot be achieved without an available product.
一种有效、安全、可逆且可接受的避孕方法是生殖健康的重要组成部分,为伴侣双方共同承担计划生育责任提供了机会。女性激素避孕药已被证明在不同人群中是安全、可逆、可用且广泛可接受的。相比之下,尽管男性激素避孕药在过去三十年中取得了显著进展,显示出与女性激素方法相当的避孕效果,但仍未推出获批产品。药物产品的安全性是合理关注的问题,但大多数男性激素避孕药临床试验并未报告重大短期安全性问题。虽然没有严重不良影响是令人鼓舞的,但这些研究是为疗效终点而设计的,而不是长期安全性。在这篇综述中,我们总结了潜在的风险和益处,即假设的男性激素避孕药对生殖和非生殖器官的影响。虽然这篇综述涵盖了我们认为可能用于男性激素避孕的药物类别,但如果没有可用的产品,就无法对长期风险和益处进行真正的评估。